{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination triggers a local type I interferon response, leading to broader antigen presentation.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
                    "line_ref": "L28"
                },
                {
                    "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
                    "line_ref": "L31"
                },
                {
                    "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
                    "line_ref": "L39"
                }
            ],
            "caveat": "The direct linkage between the interferon response and the broadened antigen presentation is an inference, though strongly supported by the data."
        },
        {
            "claim_id": "C02",
            "claim": "The vaccination-induced changes render tumors more susceptible to immune checkpoint blockade.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x",
                    "line_ref": "L32"
                },
                {
                    "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
                    "line_ref": "L33"
                }
            ],
            "caveat": "This is a mechanistic claim primarily supported by preclinical models."
        },
        {
            "claim_id": "C03",
            "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in human patients treated with ICIs.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A",
                    "line_ref": "L30"
                },
                {
                    "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
                    "line_ref": "L49"
                }
            ],
            "caveat": "This is a retrospective, non-randomized finding and may be subject to confounding."
        },
        {
            "claim_id": "C04",
            "claim": "The combination of intratumoral mRNA vaccine and anti-PD-L1 therapy leads to improved tumor control in mice.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                },
                {
                    "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
                    "line_ref": "L36"
                },
                {
                    "quote": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
                    "line_ref": "L37"
                }
            ],
            "caveat": "These are preclinical results in murine models, which may not fully translate to human cancers."
        }
    ]
}